Drug Trial Radar · NCT06205641
A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza A
Last checked: Nov 20, 2026Latest source record: Jan 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
584
Planned (sponsor's estimate)
Start
Jan 2024
Primary completion
Jun 2024
Study completion Jan 2025
Sponsor
- Lead sponsor
- Capital Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, multicenter, randomized controlled trial and aims to evaluate efficacy and safety of Xuanfei Baidu Granule in the treatment of influenza A. This study plans to enroll 584 subjects. The subjects will be randomly divided into 4 groups according to the ratio of 1:1:1:1, and they will be treated with Xuanfei Baidu Granule Placebo, Xuanfei Baidu Granule, Xuanfei Baidu Granule combined with Baloxavir Marboxil tablet.1 bag of Xuanfei Baidu Granule and Xuanfei Baidu Granule Placebo in the morning and evening, and take with boiling water for 5 days. Baloxavir Marboxil Tablet was taken orally 2 tablets, once a day for 1 day. The subjects were visited every day for 7 days after enrollment.
Conditions
- Influenza A
Interventions
Xuanfei Baidu Granule PlaceboDrug
Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.
Xuanfei Baidu GranuleDrug
Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
Baloxavir Marboxil TabletDrug
Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The time to fever resolution.Time frame: within 7 days of enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.